Nourish, a leading dietitian-led metabolic health clinic, has successfully closed a $100 million Series C funding round. The investment, led by Menlo Ventures, elevates the company's total funding to $215 million. This capital infusion will fuel Nourish's mission to combat chronic disease through its innovative, AI-driven virtual care model that integrates personalized nutrition with medical support.
Addressing a National Health Crisis
The United States faces a significant healthcare challenge, with nearly 200 million Americans living with nutrition-related chronic conditions. These diseases are the primary drivers of the nation's nearly $5 trillion annual healthcare expenditure. Nourish aims to address this crisis by shifting the focus from reactive treatments to proactive, preventative care that is both accessible and affordable.
According to CEO Aidan Dewar, the current healthcare system is ill-equipped to manage chronic illness, often providing fragmented and expensive care. Nourish was built to counter this by driving the necessary behavior and lifestyle changes for real clinical results. The company's model offers a low-cost, patient-centric alternative that delivers measurable health improvements through sustained engagement.
An AI-Powered Approach to Metabolic Health
Every patient at Nourish is paired with a Registered Dietitian for virtual consultations and a comprehensive, personalized care plan. This plan can include lab testing, medication management, and other medical services coordinated with the patient's existing healthcare providers. The goal is to provide holistic, integrated support for long-term health and sustainable outcomes.
A key differentiator for Nourish is its integration of artificial intelligence into the care process. Patients utilize an AI health agent via a mobile app to support behavior change, while providers use an AI copilot to gain insights and automate administrative tasks. This technology enhances both the quality and efficiency of care delivery, improving the experience for all parties.
Integrating GLP-1s with Sustainable Care
Amid the rising popularity of GLP-1 medications, Nourish provides a crucial support system for patients. The company addresses the high discontinuation rates of these drugs by integrating responsible prescribing with sustained nutrition and behavior coaching. This combined approach ensures that patients achieve lasting outcomes beyond medication alone, promoting long-term wellness.
The effectiveness of this model is demonstrated by impressive clinical outcomes, including an average of 8% weight loss and a 1.3-point reduction in A1C levels. These results translate into significant financial benefits, saving health plans over $2,000 per patient annually. This proves the model is both clinically effective and economically viable for payers.
Strategic Growth and Investor Confidence
The new funding will be strategically deployed to expand Nourish's clinical network and accelerate its investment in AI technology. The company also plans to deepen its partnerships with health plans, employers, and health systems. As part of the investment, J.P. Sanday of Menlo Ventures will join the board of directors, providing strategic guidance.
In just four years, Nourish has achieved remarkable scale, growing its network to over 10,000 Registered Dietitians and conducting millions of appointments. The company has partnered with hundreds of health plans, making its services available to over 200 million Americans. This rapid expansion highlights the significant demand for its accessible, insurance-covered care model.
This $100 million investment marks a pivotal moment for Nourish, validating its unique approach to metabolic health. By combining expert clinical care with advanced AI, the company is well-positioned to scale its impact on chronic disease management. The funding will enable Nourish to expand its reach and fundamentally change how healthcare addresses long-term, nutrition-related conditions across the country.